🩺 Clinically, identifying a lactose fermenting GNR is particularly useful for ruling out Pseudomonas.

⚠️ Many non-lactose fermenters (especially Stenotrophomonas, Burkholderia, and Acinetobacter) can be very challenging to treat. ID consultation should be considered for invasive infections.

Yay! Tara's our awesome ASP track fellow this year - so lucky to get to work with her! @stanfordasp.bsky.social @linameng.bsky.social @dhpharmd.bsky.social @polishmd.bsky.social

Risks of ABX overuse greater than benefit? 🤔

The same treatment was associated with negative outcomes, including increased hospital readmissions, transfers to the ICU, and longer hospital stays. 🏥

The outcome: After adjustment, empiric broad-spectrum antibiotic treatment was not associated with a lower mortality rate. 🚫

🔎 The findings: In 2,706 moderately ICH patients with pneumonia, MRSA and resistant GNB were rare, found in just 3.5% of cases. 📉

Check this-CLSI eliminated gentamicin as tx option for PsA.

"Review of modern PK/PD) data against members of the Enterobacterales and P. aeruginosa demonstrated:

• No safe aminoglycoside dosing regimen was predicted to achieve bacterial 1- or 2-log killing, regardless of the breakpoint applied."

I'm hoping it's because they were super users at baseline 🤓

Implementing microlearning via ABX Pearls emailed to clinicians and trainees weekly at our hospital. 81% reported an impact on their practice, across multiple stewardship domains. 👇🏻

Library here:
med.stanford.edu/bugsanddrugs...

#IDPharmacistsDay #medEd #AMSsky

Hi! Lina here from Stanford, CA. I love working with the innovative, bright, open-minded ASP team here @stanfordasp.bsky.social and learning from amazing, dedicated pharmDs/MDs nationally that have propelled ABX stewardship forward tremendously in recent years. #IDpharmacistsday

Yes Epic+beaker. Agh that's tough when you have lab limitations